Cited by 892Cancer Cells and MetastasisAcute Lymphoblastic Leukemia researchDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.

Environment-mediated drug resistance: a major contributor to minimal residual disease

Meads, Mark B., Gatenby, Robert A., Dalton, William S.·2009·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Environment-mediated drug resistance is a form of de novo drug resistance that protects tumour cells from the initial effects of diverse therapies. Surviving foci of residual disease can then develop complex and permanent acquired resistance in response to the selective pressure of therapy. Recent evidence indicates that environment-mediated drug resistance arises from an adaptive, reciprocal signalling dialogue between tumour cells and the surrounding microenvironment. We propose that new therapeutic strategies targeting this interaction should be applied during initial treatment to prevent the emergence of acquired resistance.

Integrity signals

Registry

Crossref · 10.1038/nrc2714

Cites

109 of 109 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Treatment of Acute Lymphoblastic Leukemia
Pui, C., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 2,012
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G. W., Davé, S. S., Xiao, W., Powell, J. I., Zhao, H., Xu, W., Tan, B. T., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,847
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Mundy, G. R., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B. F., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,776
Stromal gene expression predicts clinical outcome in breast cancer
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Ömeroğlu, G., Meterissian, S. H., Ömeroğlu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,707
Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citation
Reversion of the Malignant Phenotype of Human Breast Cells in Three-Dimensional Culture and In Vivo by Integrin Blocking Antibodies
Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483
A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer
Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., Schlimok, G., Diel, I., Gerber, B., Gebauer, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050434 · Cited by 1,380
DQIS — Distributed Quorum-Based Independent Immune Surveillance: A Theoretical Framework for Byzantine Fault Tolerance for Multi-Channel Immune Surveillance
DQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,333

Show all 109 references

Research works printed but not linked: 1

Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 63, 1727–1733 (1979).

Sorted by citations

Items 701–800 of 892

Secretion of IL-6 and TGF-β2 by Colon Cancer Cells May Promote Resistance to Chemotherapy
Sritharan, S., & Sivalingam, N. (2024) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-024-01247-3 · Cited by 4
Biomimetic chitosan-based scaffold for 3D breast cancer cell culture: a promising tool for anticancer drug screening
Setiawati, A., Kencana, N. B. W., Putra, H. S. D., Kencana, M. V. S. A., Ajiteru, O., Yoga, I. M. B. K., Fatimah, N., & Hermawan, A. (2025) · Macromolecular Research · doi:10.1007/s13233-025-00405-7 · Cited by 3
Three-dimensional tumor model and their implication in drug screening for tackling chemoresistance
Priyadarshini, M., Mohanty, S., Mahapatra, T., Mohapatra, P., & Dash, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818128-7.00020-4 · Cited by 3
Tumor immunology
Sharif, P. M., Khoshbin, A. P., Nasrollahzadeh, E., Keshavarz‐Fathi, M., & Rezaei, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818006-8.00003-7 · Cited by 3
Study on the mechanism of CXCL12/CXCR4-axis-mediated upregulation of IL-8 and IL-6 on the biological function of acute T lymphocyte leukaemia cells
Zhou, L., Zhao, H., Zhang, C., Chen, Z., Li, D., & Qian, G. (2023) · Cytotechnology · doi:10.1007/s10616-023-00600-3 · Cited by 3
Microsphere‐Enabled Modular Formation of Miniaturized In Vitro Breast Cancer Models
Wang, W., Zhang, L., O'Dell, R., Yin, Z., Yu, D., Chen, H., Liu, J., & Wang, H. (2023) · Small · doi:10.1002/smll.202307365 · Cited by 3
Biology of Metastatic Liver Tumors
Wells, A. H., Chao, Y. L., & Wu, Q. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-7107-4_58 · Cited by 3
Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cells
Zhang, C., Zhang, X., Yang, S., & Chen, X.-H. (2017) · Oncology Letters · doi:10.3892/ol.2017.5686 · Cited by 3
Proliferation Pattern of Pediatric Tumor-Derived Mesenchymal Stromal Cells and Role in Cancer Dormancy: A Perspective of Study for Surgical Strategy
Pelizzo, G., Riva, F., Croce, S., Avanzini, M. A., Acquafredda, G., SILVESTRI, A. D., Mazzon, E., Bramanti, P., Zuccotti, G., Mazzini, G., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.766610 · Cited by 4
Genetic and Environmental Determinants in Multiple Myeloma: Implications for Therapy
Shain, K. H., & Dalton, W. S. (2012) · Springer eBooks · doi:10.1007/978-94-007-5028-9_4 · Cited by 3
Self-citation
Unmasking circulating tumor cells
Swennenhuis, J. F. (2016) · doi:10.3990/1.9789036542685 · Cited by 3
Targeting DDR1 and DDR2 overcomes matrix-mediated melanoma cell adaptation to BRAF-targeted therapyPreprint
Berestjuk, I., Lecacheur, M., Diazzi, S., Rovera, C., Prod’homme, V., Mallavialle, A., Larbret, F., Pisano, S., Audebert, S., Passeron, T., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/857896 · Cited by 3
Validation of a Mathematical Model of Cancer Incorporating Spontaneous and Induced Evolution to Drug ResistancePreprint
Gevertz, J. L., Greene, J. M., & Sontag, E. D. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2019.12.27.889444 · Cited by 3
Extended sub-chronic exposure to heavy metal mixture induced multidrug resistance against chemotherapy agents in ovarian cancer cells
Sahin, G., & Doğanlar, Z. B. (2025) · Toxicology Letters · doi:10.1016/j.toxlet.2025.03.006 · Cited by 2
Diagnosis and therapeutic targeting of quiescent cancer cells: road to conquer cancer recurrence
Kim, M. J. (2025) · BMB Reports · doi:10.5483/bmbrep.2025-0007 · Cited by 2
Increased efficacy of PARP inhibitors against cisplatin-sensitive and -resistant ovarian cancer cells mediated via ATR and ATM inhibition
König, P., Bade, L., Eichhorn, J. M., Skalski, H., Cinatl, J. J., Michaelis, M., & Bendas, G. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02740-1 · Cited by 2
A metabolic trade-off between malignant plasma cells and mesenchymal stromal cells sustains multiple myeloma growth
Taurino, G., Griffini, E., Toscani, D., Maccari, C., Tardito, S., Bianchi, M. G., Casati, L., Dander, E., D’Amico, G., Andreoli, R., et al. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100195 · Cited by 2
CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival
Madiot, C., Bellanger, C., Dousset, C., Decombis, S., Thirouard, L., Papin, A., Baron, E., Barc, J., Bris, Y. L., Gomez‐Bougie, P., et al. (2026) · Leukemia · doi:10.1038/s41375-026-02894-6 · Cited by 1
Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies
Caserta, S., Martino, E. A., Vigna, E., Skafi, M., Bruzzese, A., Amodio, N., Lucia, E., D’Arrigo, G., Olivito, V., Labanca, C., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70203 · Cited by 2
Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets
Zhang, K.-Y., Zhu, X.-Z., Yan, Y., Ying, X.-H., Zhang, J., & Wang, Z. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02850-x · Cited by 3
Models for Evaluation of Targeted Therapies of Invasive and Metastatic Disease
Eccles, S. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-968-0_19 · Cited by 2
Improvement of Cancer Therapy Using Phytochemicals
Roy, M., & Datta, A. (2019) · Springer eBooks · doi:10.1007/978-981-13-9471-3_6 · Cited by 2
Influence of paclitaxel therapy on expression of ßIII-Tubulin and Carbonic anhydrase IX proteins in chemically-induced rat mammary tumors
Hladová, A., Hodorová, I., Rybárová, S., Mihálik, J., Bobrov, N., Solár, P., Benetinová, Z., & Mirossay, L. (2020) · Biologia · doi:10.2478/s11756-020-00496-w · Cited by 2
Heterogeneous Tumour Modeling Using PhysiCell and Its Implications in Precision Medicine
Savić, M., Kurbalija, V., Balaž, I., & Ivanović, M. D. (2022) · Emergence, complexity and computation · doi:10.1007/978-3-031-04379-6_7 · Cited by 2
Leukemia circulation kinetics revealed through blood exchange method
Miller, A. B., Rodriguez, F. H., Langenbucher, A., Lin, L., Bray, C., Duquette, S. M., Zhang, Y., Goulet, D. R., Lane, A. A., Weinstock, D. M., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06181-x · Cited by 2
Establishment of a tumor-associated fibroblast associated gene score based on scRNA-seq to predict prognosis in patients with triple-negative breast cancer
Yu, H., Peng, Z., Li, X., & Zhang, Y. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311801 · Cited by 2
Mathematical and Computational Models in Cancer
Chowbina, S., Janes, K. A., Peirce, S. M., & Papin, J. A. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-478-4_6 · Cited by 2
Wnt sinyal yolağı ve kanser
Güneş, B. A. (2016) · Ankara Sa · doi:10.1501/ashd_0000000118 · Cited by 2
Role of mesenchymal stem cells in tumor microenvironment
Mir, M. A., Mir, A. Y., Jan, U., Dar, M. A., & Shah, M. Z. U. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-443-18696-7.00004-x · Cited by 2
Cancer Stem Cells
Balla, M. M. S., Kusumbe, A. P., Vemuganti, G. K., & Bapat, S. A. (2010) · Springer eBooks · doi:10.1007/978-90-481-9075-1_15 · Cited by 2
Cancer Stem Cells: Biology and Potential Therapeutic Applications
Mangoni, M., Sottili, M., Loi, M., Gerini, C., Meattini, I., & Livi, L. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_8 · Cited by 2
Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia
Sivagnanalingam, U., Balys, M. M., Eberhardt, A., Wang, N., Myers, J. R., Ashton, J. M., Becker, M. W., Calvi, L. M., & Mendler, J. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132375 · Cited by 3
Republished: Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology
Valcz, G., Sípos, F., Tulassay, Z., Molnar, B. A., & Yagi, Y. (2015) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-202561rep · Cited by 3
Targeting the TumorMicroenvironment for Enhancing Chemotherapy in HematologicMalignancies
Crespo, L., Zhang, X., & Tao, J. (2010) · Springer eBooks · doi:10.1007/978-90-481-9704-0_11 · Cited by 2
Impact of Biomarkers Expression Before and After Portal Vein Embolization on Recurrence After Two-Stage Hepatectomy for Colorectal Liver Metastases
Narita, M., Oussoultzoglou, É., Chenard, M., Fuchshuber, P., Rosso, E., Pessaux, P., Jaeck, D., & Bachellier, P. (2011) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-011-1732-2 · Cited by 2
Emerging Themes in Drug Resistance
Arora, G., Kulshreshtha, A., Arora, K., Talwar, P., Raj, R., Grewal, G. K., Sajid, A., & Kukreti, R. (2017) · Springer eBooks · doi:10.1007/978-3-319-48683-3_1 · Cited by 2
The Local Recurrence of Breast Cancer with Squamous Metaplasia and Obvious Histological Heterogeneity
Yamashita, N., Tokunaga, E., Yamamoto, H., Shimizu, C., Taketani, K., Inoue, Y., Saeki, H., Oki, E., & Maehara, Y. (2017) · Anticancer Research · doi:10.21873/anticanres.11949 · Cited by 2
Clinical Applications of Tumor-targeted Systems
Zhang, X. (2020) · Springer eBooks · doi:10.1007/978-981-15-5159-8_13 · Cited by 2
Case report: Post-therapeutic laryngeal carcinoma patient possessing a high ratio of aneuploid CTECs to CTCs rapidly developed de novo malignancy in pancreas
Mi, J., Yang, F., Liu, J., Liu, M., Lin, A. Y., Wang, D. D., Lin, P. P., & Zeng, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.981907 · Cited by 2
Transcription of WNT Genes in Hematopoietic Niche’s Mesenchymal Stem Cells in Multiple Myeloma Patients with Different Responses to Treatment
Enukashvily, N. I., Belik, L. A., Semenova, N. Y., Kostroma, I. I., Motyko, E., Gritsaev, S. V., Бессмельцев, С. С., Sidorkevich, S. V., & Мартынкевич, И. С. (2023) · Genes · doi:10.3390/genes14051097 · Cited by 2
MYC and MiR: vicious circle
Zhao, X., Zhang, X., & Tao, J. (2013) · Oncotarget · doi:10.18632/oncotarget.1602 · Cited by 2
Plasticidade molecular da matriz extracelular contribui para metástase e resistência a terapias / Molecular plasticity of the extracellular matrix contributes to metastasis and resistance to therapies
Barbosa, A. E. D. S., Azevedo-Martins, J. M., Lopes, B. A., Giardini, I. J. M., & Halder, C. V. F. (2021) · Brazilian Journal of Health Review · doi:10.34119/bjhrv4n4-250 · Cited by 2
Nano-enabled pharmacogenomics: revolutionizing personalized drug therapy
Tıwarı, R., Dev, D., Thalla, M., Aher, V. D., Mundada, A. B., Mundada, P. A., & Vaghela, K. (2024) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2024.2431426 · Cited by 11
First report of multidrug-resistant and pathogenic Plesiomonas shigelloides from endangered crested ibis (Nipponia nippon)
Xia, J., Shao, L., Chen, X., Ji, Y., Ma, W., Chen, K., Qiu, G., Song, H., & Yang, Y. (2025) · BMC Veterinary Research · doi:10.1186/s12917-025-04755-3 · Cited by 1
Matrix-free microfluidic 3D biomimetic chip for identifying type I collagen on doxorubicin treated MDA-MB-231 cell
Wu, Q., Jin, S., Chang, S., Xu, S., Xu, Z., Zeng, S., Huang, X., & Ma, H. (2025) · Microfluidics and Nanofluidics · doi:10.1007/s10404-025-02827-2 · Cited by 1
Epithelial–mesenchymal transition and cancer-associated fibroblasts in tumor progression and therapy resistance: mechanistic convergence and therapeutic opportunities
Singh, D. K., Gupta, R., Kumar, U., & Gupta, S. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04255-2 · Cited by 1
Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer
Cruz, P., Boixareu, C., Silva, D., Ting, J., Sena, R. H. R., Pang, S. A., Mullings, S., & Minchom, A. (2026) · Cancers · doi:10.3390/cancers18050880 · Cited by 1
Integrating multi-omics data for next-generation cancer research and precision medicine
Biswas, S., Acharya, S., Prajapat, A., Sen, P., Desai, S., Giri, S., Matthiesen, R., CAPCI, T., Chaubey, G., & Suravajhala, P. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04368-8 · Cited by 1
Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma
Canevarolo, R. R., Sudalagunta, P. R., Meads, M. B., Silva, M., Zhao, X., Magaletti, D. M., Alugubelli, R. R., DeAvila, G., Deavila, D., Persi, E., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-26-1082 · Cited by 1
Self-citation
The Shape-Shifting Myeloma: Adaptive Plasticity as a Hallmark of Relapse and Refractoriness
Nasso, M. E., Bottaro, A., Gerace, D. G., Russo, S., Mannina, D., & Allegra, A. (2026) · Cancers · doi:10.3390/cancers18121873 · Cited by 1
Reprogramming the Tumor Oncobiosphere: Bioactive Nanohybrid Materials for Reversing Therapeutic Pseudo-Resistance
Rejinold, N. S., Jin, G., & Choy, J. (2026) · ACS Omega · doi:10.1021/acsomega.6c00998 · Cited by 1
Modeling cancer with bacteria-integrated tumor microenvironments using biomaterials: Emerging concepts and opportunities
Jeon, K., Kim, U., Ji, C.-H., Kamaraj, M., Laird, N. Z., Wang, Z., Yu, H., Ermis, M., Sullan, R. M. A., Shen, X., et al. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103330 · Cited by 1
Allosteric kinase inhibition in hematological malignancies: from asciminib to emerging regulatory sites
Marx, A., Cohen, M., Ruthardt, M., & Mahajna, J. A. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118436 · Cited by 1
La mitocondria: un nuevo paradigma en oncología
Aragó, M. S., & Cuezva, J. M. (2012) · Monografías de la Real Academia Nacional de Farmacia · Cited by 1
Biological Significance of Apoptosis in Ovarian Cancer: TRAIL Therapeutic Targeting
Goncharenko-Khaider, N., Lane, D. A., Matte, I., Rancourt, C., & Piché, A. (2013) · InTech eBooks · doi:10.5772/53380 · Cited by 1
How Cancer Outsmarts Treatments: Assessing Drug Resistance in Tumors
Xiao, Q., Zheng, L., Wu, A. A., Kimmel, S., & Goldman, S. Y. (2013) · Cited by 1
Stromal Biomarkers as Putative Targets in Cancer Chemotherapy
Carasevici, E. (2012) · Biochemistry & Pharmacology Open Access · doi:10.4172/2167-0501.1000e108 · Cited by 1
Organoid Culture: Applications in Development and Cancer
Cañadas, I., & Barbie, D. A. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-45397-2_3 · Cited by 1
Targeting apoptosis is the major battle field for killing cancers
Liu, X. (2015) · World Journal of Translational Medicine · doi:10.5528/wjtm.v4.i3.69 · Cited by 1
Nano drug delivery strategies for the treatment and diagnosis of oral and throat cancers
Perdomo, S. J., Fonseca-Benítez, A. V., Cardona-Mendoza, A., Romero‐Sánchez, C., & Párraga, J. E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819793-6.00004-7 · Cited by 1
Inherited GATA3 variant associated with positive minimal residual disease in childhood B‐cell acute lymphoblastic leukemia via asparaginase resistance
Li, C., Liang, W., He, Y., Zhao, X., Qian, J., Li, Z., Jiang, C., Zheng, Q., Fu, X., Zhang, W., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.507 · Cited by 1
The Bone Marrow Microenvironment: Novel Targets to Circumvent Minimal Residual Disease and Drug Resistance in Multiple Myeloma
Shain, K. H., & Dalton, W. S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4666-8_8 · Cited by 2
Self-citation
Anti-CD20 antibody treatment for diffuse large B cell lymphoma: Genetic alterations and signaling pathways
Jin, Y., Wang, C., Li, Y., Cho, W. C. S., & Song, G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19200-5.00002-6 · Cited by 1
Tumor Inflammatory Microenvironment in Lung Cancer: Heterogeneity and Implications
Bhatia, A., Sobti, R. C., & Sharma, S. (2023) · Springer eBooks · doi:10.1007/978-981-99-2196-6_20-1 · Cited by 1
Use of atomic force microscopy to assess the biomechanical properties of 3D tumor cell models
Puchkova, K. S., Lopareva, V. R., Shepeleva, E. V., Magomedova, O. A., Ivanova, D. V., & Zamskaya, Y. V. (2024) · Genes and Cells · doi:10.17816/gc631097 · Cited by 1
Development and validation of a prognostic prediction model for endometrial cancer based on CD8+ T cell infiltration-related genes
Chen, C., Pei, L., Ren, W., & Sun, J. (2024) · Medicine · doi:10.1097/md.0000000000040820 · Cited by 1
The Bone Marrow Microenvironment and Its Impact in Acute and Chronic B Cell Malignancies
Burger, J. A., & Sipkins, D. A. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4174-7_3 · Cited by 1
The Complexity of Colorectal Cancer Biology — Putting Bricks on the Path to Personalized Medicine
Balboa, E., Carracedo, Á., & Barros, F. (2014) · InTech eBooks · doi:10.5772/57172 · Cited by 1
Neoplasms in the bone marrow niches: disturbance of the microecosystem
Mu, L., Ke, F., Guo, X., Cai, J.-J., & Hong, D. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2193-5 · Cited by 1
Stratifying Cancer Therapies by Molecular Interactions and Imaging
Galazi, M., Weitsman, G. E., Monypenny, J., Coban, O., Milewicz, H., Gómez, V., Ciccarelli, F. D., & Ng, T. (2017) · Springer eBooks · doi:10.1007/978-3-319-53661-3_15 · Cited by 1
Cancer Cells Impair the Clearance of Oncolytic Virus M1 By Macrophage in a Non-Contact-Dependent Manner
Hu, J. X. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.18.003132 · Cited by 1
Synthesis of thioridazine-VLA-4 antagonist hybrids usingN-propargyl northioridazine enantiomers
Martyn, A. P., Willis, A. C., & Kelso, M. J. (2020) · Synthetic Communications · doi:10.1080/00397911.2020.1785503 · Cited by 1
Expression, Functions And Potential Therapeutic Implications Of CD157 In Acute Myeloid Leukemia
Yakymiv, Y. (2020) · Stem Cells Research Development & Therapy · doi:10.24966/srdt-2060/100038 · Cited by 1
Cancer Stem Cells and the Stromal Microenvironment
Li, L., & Margolin, D. A. (2014) · doi:10.1002/9781118356203.ch21 · Cited by 1
Targeting the Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-kB) Pathway to Overcome Cisplatin-Resistance in Non-Small Cell Lung Cancer
Ryan, S.-L. (2019) · Queensland University of Technology · doi:10.5204/thesis.eprints.127346 · Cited by 2
Cell-Intrinsic and Extrinsic Effects of Galectin-1 and Galectin-3 in B-Cell Precursor Acute Lymphoblastic LeukemiaPreprint
Fei, F., Joo, E. J., Yang, L., Groffen, J., & Heisterkamp, N. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.22.461145 · Cited by 1
Identification of the Dysregulated Pathways and Key Gene in Prostate Cancer by Transcriptome Analysis and Cell Biology ExperimentsPreprint
Sun, W., Guo, J., Cheng, Z., Zhang, Y., & Gao, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1122595/v1 · Cited by 1
Targeting Myeloid Protein Kinase C Signaling to Overcome Immune Suppression and Improve Immunotherapy in Cancer
Chaib, M. (2022) · doi:10.21007/etd.cghs.2022.0613 · Cited by 1
CAF-released galectin 1 mediates non-cell-autonomous resistance to ceritinib in NSCLC.Preprint
Rizzolio, S., Orrù, C., Volante, M., Bellomo, S. E., Migliore, C., Giordano, S., & Corso, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3192164/v1 · Cited by 1
Etablissement d'un nouveau modèle pérclinique de cancer de la prostate et identification de biomarqueurs de résistance au docetaxel
Nakouzi, N. A. (2011) · theses.fr (ABES) · doi:10.70675/4e4b277az83fbz4562zbae0z9f48206f14aa · Cited by 1
Effect of tumor microenvironment-derived factors on melanoma cell growth and drug-response : an in vitro study in three-dimensional cultures.
Rist, M. (2011) · NORA - Norwegian Open Research Archives
Análise de expressão do gene ADAM23 em tumores do sistema nervoso central (SNC) e estudo de sua função em gliomas e em melanomas
Ferreira, T. Z. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2012.tde-23042013-104141
Rational therapeutic options for patients with myeloproliferative neoplasms.
Hoffman, R. (2011) · PubMed Central
The role of short-term starvation in sensitizing breast cancer to chemotherapy
Govender, Y. (2013) · SUNScholar (Stellenbosch University)
Engineered 3D models to study the cancer microenvironment as a determinant of drug response
Håkanson, M. (2011) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-a-006706762
Emerging Opportunities for Targeting the Tumor–Stroma Interactions for Increasing the Efficacy of Chemotherapy
Nair, R. R., Gebhard, A. W., & Hazlehurst, L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_3
PROTEASOME INHIBITION ENHANCES THE EFFECT OF BIKDD GENE THERAPY
Sun, Y. (2014) · Digital Commons-TMC (Texas Medical Center)
521 Cell Cycle Regulation Changes in Drug-Resistant Cancers
Safuwan, N. A. M., Crook, T., & Coley, H. M. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)72318-3
The micros in harmony: microRNA and microenvironment
Balakrishnan, K., & Gandhi, V. V. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.598252
Characterization of a Mouse Model of Soft Tissue Sarcoma: Intraoperative Molecular Imaging and miRNA Regulation of Metastasis
Mito, J. K. (2013) · DukeSpace (Duke University)
The Stem Cell Niche and Its Role in Self-Renewal, Aging, and Malignancy
Breslin, S. J. P., Volk, A. G., & Zhang, J. (2013) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.201200010
Le nt tumoral résistance
DeClerck, Y. A. (2014)
Characterisation of the in vitro properties of pacritinib (SB1518) in Acute Myeloid Leukaemia
Marrin, C. (2015) · ORCA Online Research @Cardiff (Cardiff University)
Chemotherapy: PIFAs de resistance
Legg, K. (2011) · Lipidomics Gateway · doi:10.1038/lipidmaps.2011.31
Tumor acidosis in malignant progression and therapy
Pellegrini, P. (2016) · Figshare
A Trans-Dimensional View of Drug Resistance Evolution in Multiple Myeloma Patients
Jacobson, T. (2016) · Digital Commons - University of South Florida (University of South Florida)
[Effect of VE-cadherin on sensitivity to Imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells].
Zhang, H., Chen, C., Yan, Z., Song, X., Chen, W., Li, D., Qiu, T., Zhang, P. X., Zeng, L., Li, Z., et al. (2013) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2013.06.014
The Tumor Microenvironment as a Target for Therapeutic Intervention
Hua, F., & DeClerck, Y. A. (2015) · Wiley eBooks · doi:10.1002/9781118468678.ch5
Understanding of ‘Networks’ In Vitro and/or In Vivo
Schoof, E. M., Ferkinghoff‐Borg, J., & Linding, R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.40027-1
Galectins and Pathologies: Role of Galectin-3 in the Communication between Leukemia Cells and the Microenvironment
Heisterkamp, N., Fei, F., & Groffen, J. (2012) · ACS symposium series · doi:10.1021/bk-2012-1115.ch014

Authors: Meads, M. B., Gatenby, R. A., & Dalton, W. S.
Affiliations: Moffitt Cancer Center (US)
Corresponding author: Dalton, William S.
ORCID: Meads, Mark B.
Gatenby, Robert A.
Dalton, William S.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2009-08-20
Volume: 9
Issue: 9
Pages: 665-674
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc2714
OpenAlex: W2066616821
Cited by: 892
References: 109
Citations by year: 2026: 33 · 2025: 44 · 2024: 35 · 2023: 55 · 2022: 54 · 2021: 74 · 2020: 65 · 2019: 58 · 2018: 56 · 2017: 52 · 2016: 68 · 2015: 61 · 2014: 64 · 2013: 51 · 2012: 52
FWCI: 3.53
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords: tumor microenvironment, minimal residual disease, recurrence, acquired drug resistance, stromal factors, adjuvant therapy, cancer therapy resistance
MeSH terms: Humans, Neoplasms, Signal Transduction, Stromal Cells, Neoplasm, Residual, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Environment-mediated drug resistance: a major contributor to minimal residual disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks